AMBRX BIOPHARMA INC-ADR
1 day chart
Ambrx Biopharma Inc. is a clinical-stage biologics company. The Company is focused on discovering and developing a class of engineered precision biologics (EPBs), using its expanded genetic code technology platform that allows to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation. Its SAA incorporation technology allows to develop a range of product candidate modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates (ISACs). Its lead advanced internal product candidate is ARX788, an anti-HER2 ADC, being investigated in multiple clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer and other solid tumors.
Buy US stocks in Australia with $0 brokerage and trade AMAM today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.